Vapreotide
Overview
Vapreotide is a synthetic octapeptide analog of somatostatin with enhanced selectivity for somatostatin receptor subtypes 2 and 5. It exerts antisecretory and antiproliferative effects by binding to these receptors on neuroendocrine tumor cells and inhibiting hormone release. The therapeutic rationale centers on control of symptoms associated with vasoactive intestinal peptide secreting tumors and other neuroendocrine malignancies. Its longer half-life compared to native somatostatin allows for sustained receptor occupancy.
Key Research Findings
Clinical trials evaluated vapreotide for acute variceal bleeding and neuroendocrine tumor symptom control, though efficacy compared to octreotide was not consistently superior. The compound has been studied in phase III trials but did not achieve broad regulatory approval for oncology indications. Most clinical experience is derived from European studies in the 1990s and early 2000s.
Subcutaneous injection, Intravenous
Investigational
Interested in Vapreotide?
Find a verified provider experienced with Vapreotide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Vapreotide ProviderRelated Peptides
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S proteasome. By blocking proteasomal degradation of ubiquitinated proteins, carfilzomib causes accumulation of misfolded proteins, endoplasmic reticulum stress, and activation of the unfolded protein response, leading to apoptosis preferentially in malignant plasma cells. Its irreversible binding confers greater proteasome inhibition than bortezomib.
Bortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortezomib disrupts the ubiquitin-proteasome pathway, stabilizing pro-apoptotic factors and inhibiting NF-kB activation, which is constitutively active in many hematologic malignancies. It was the first proteasome inhibitor approved for cancer treatment and fundamentally changed the treatment landscape of multiple myeloma.
Lutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioisotope lutetium-177. Lutathera binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells, delivering targeted radiation therapy directly to tumor cells while sparing surrounding normal tissue. This peptide receptor radionuclide therapy (PRRT) approach combines receptor-targeted delivery with cytotoxic radiation.
Leuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in premenopausal breast cancer. Chronic administration produces sustained downregulation of pituitary GnRH receptors, achieving medical castration with testosterone levels below 50 ng/dL. The initial testosterone flare can be mitigated by co-administration of an antiandrogen. Depot formulations provide sustained release for up to 6 months.